<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJU</journal-id><journal-title-group><journal-title>Open Journal of Urology</journal-title></journal-title-group><issn pub-type="epub">2160-5440</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/oju.2018.85016</article-id><article-id pub-id-type="publisher-id">OJU-84487</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Diagnosis and Management of Prostate Cancer in Urology
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Cyril</surname><given-names>Kamadjou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kimassoum</surname><given-names>Rimtebaye</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Divine</surname><given-names>Eyongeta</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Annie</surname><given-names>Kameni</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Justin</surname><given-names>Kamga</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bertin</surname><given-names>Njinou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>General Hospital, Yaounde, Cameroon</addr-line></aff><aff id="aff2"><addr-line>National General Referal Hospital, N’Djamena, Chad</addr-line></aff><aff id="aff1"><addr-line>Medico-Surgical Center of Urology and Mini Invasive Surgery, Douala, Cameroon</addr-line></aff><aff id="aff3"><addr-line>Regional Hospital, Limbe, Cameroon</addr-line></aff><pub-date pub-type="epub"><day>10</day><month>05</month><year>2018</year></pub-date><volume>08</volume><issue>05</issue><fpage>161</fpage><lpage>165</lpage><history><date date-type="received"><day>26,</day>	<month>February</month>	<year>2018</year></date><date date-type="rev-recd"><day>8,</day>	<month>May</month>	<year>2018</year>	</date><date date-type="accepted"><day>11,</day>	<month>May</month>	<year>2018</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Introduction: Describe the diagnostic approach and management of prostate cancer at the medico-surgical center of urology in Douala, Cameroon. 
  Materials and methods: This was a descriptive retrospective study reviewing 100 patient’s records suffering of prostate cancer from January 2011 to December 2015. The studied variables were clinical, paraclinical and therapeutic. 
  Results: The mean age was 65 years with extrems of 50 and 85. Rectal examination was suggestive in 63 cases. 7 patients had a family history. The average PSA rate was 43.23 ng/ml. Histology has concluded to an adenocarcinoma in all patients. The gleason score was equal or greater than to 7 for 53 patients (53%). The extended assessment revealed distant metastasis for 43 patients. The treatment was: surveillance (n = 33), total laparoscopic radical prostatectomy (n = 24), surgical hormone therapy (n = 10), medical hormone therapy (n = 28) and chemotherapy coupled with hormone therapy (n = 5). 
  Conclusion: Prostate cancer is common in Douala; its diagnosis is made late. Radical treatment is possible for localized cancers, hence the interest of early detection.
 
</p></abstract><kwd-group><kwd>Prostate Cancer</kwd><kwd> Adenocarcinoma</kwd><kwd> Prostatectomy</kwd><kwd> Hormone Therapy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Prostate cancer is the first urological cancer of men and the second leading cause of death caused by cancer [<xref ref-type="bibr" rid="scirp.84487-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.84487-ref2">2</xref>] . The advent of PSA and the development of medical imaging allow early diagnosis at a localized stage making possible curative treatment. In developing countries where patients consult at a late symptomatic stage [<xref ref-type="bibr" rid="scirp.84487-ref3">3</xref>] , curative treatment usually gives way to palliative treatment. Emphasis should be placed on awareness and early detection so that all men over the age of 40 can consult an urologist at least once a year. The purpose of our study is to introduce our diagnostic and therapeutic approach to prostate cancer at the Medico-surgical Center of Urology (CMCU) in Douala, Cameroon.</p></sec><sec id="s2"><title>2. Materials and Methods</title><p>This was a descriptive retrospective study reviewing 100 patient’s records suffering of prostate cancer from January 2011 to December 2015for the first in CMCU. Patients came spontaneously or were referred by colleagues. Were included patients whose diagnosis of prostate cancer was selected on the basis of a panel of clinical and paraclinical arguments, and had received care at the CMCU. Were excluded those who left the follow-up and those who refused treatment when informed of the risk of erectile dysfunction or urinary incontinence after treatment. Patients with non-prostatic urologic cancers were not included. These patients had a clinical and paraclinical assessment. Clinical variables included: age, medical and family history, general condition, urinary disorders of the lower urinary tract and digital rectal examination. Paraclinical variables included total PSA, the rate of urea and blood creatinine, renal, vesical and prostatic ultrasound, transrectal prostate ultrasound-guided in sextant, histological analysis of prostate biopsy cores, the thoraco-abdominal and pelvic CT scans, magnetic resonance imaging and bone scintigraphy. The therapeutic variables included: therapeutic abstention, radical laparoscopic prostatectomy, surgical hormone therapy, medical hormone therapy and chemotherapy. The reasons for the study were explained to the patients and their consent was obtained for the anonymous use for scientific purposes of the pictures.</p></sec><sec id="s3"><title>3. Results</title><p>In three years of activities, we diagnosed 100 patients with prostate cancer, all stage toghether. The average age of the patients was 65 years with extremes of 50 and 85 years. The notion of family history (first degree of kinship) is found in 7 patients. Digital rectal examination had made possible to suspect the diagnosis of prostate cancer in 63 patients. The reasons for consultation were dominated by urinary troubles of the lower urinary tract (64%). The average PSA was 43.23 ng/ml with extremes of 5 and 217 ng/ml. The histological analysis of the prostate cores biopsy led to the diagnosis of certainty of prostate cancer in 93 cases and 7 in other cases by histological analysis of the endoscopic resection chips. Adenocarcinoma (<xref ref-type="fig" rid="fig1">Figure 1</xref>) was the only histological type found. The Gleason score was greater than 7 in 53 cases. The extented assessment permitted to objectify for 43 patients with distant metastasis (<xref ref-type="fig" rid="fig2">Figure 2</xref>). 30 cases of bone metastasis and 13 lymph nodes mestastasis. The management was surveillance (n = 33), total radical laparoscopic prostatectomy (n = 24), surgical hormonal therapy</p><p>(n = 10), medical hormone therapy (n = 28) and hormone therapy followed by chemotherapy (n = 5). During the study we registered 2 deaths from patients who received chemotherapy.</p></sec><sec id="s4"><title>4. Discussion</title><p>Prostate cancer is the first urological cancer of men and the second leading cause of death after lung cancer [<xref ref-type="bibr" rid="scirp.84487-ref4">4</xref>] . Since Huggin’s work, focusing on the hormone-dependent nature of prostate cancer and the popularization of the use of PSA, the incidence of prostate cancer is increasing in developed countries [<xref ref-type="bibr" rid="scirp.84487-ref5">5</xref>] . In Africa, epidemiological data are scarce in relation to the absence of a cancer registry as highlighted by the work of Ndoye and al [<xref ref-type="bibr" rid="scirp.84487-ref6">6</xref>] . In Nigeria, a hospital incidence of 127/100,000 for 20,000 deaths is reported [<xref ref-type="bibr" rid="scirp.84487-ref7">7</xref>] . This high incidence reported by the Nigerian study reinforces the thesis that prostate cancer is more common in black African subjects [<xref ref-type="bibr" rid="scirp.84487-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.84487-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.84487-ref10">10</xref>] . The mean age of patients is 64.85 years is similar to those found by other African authors [<xref ref-type="bibr" rid="scirp.84487-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.84487-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.84487-ref13">13</xref>] confirming that prostate cancer is a cancer of the elderly age.</p><p>The study found that patients with a family history of prostate cancer are young because they are all under 55 years of age. Familial prostate cancers are known to be more aggressive and occur at early ages. In this at-risk population, early detection from the age of 40 seems a good strategy for early management as recommended by the American Cancer Association [<xref ref-type="bibr" rid="scirp.84487-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.84487-ref14">14</xref>] . Evidence-based on rectal examination in sixty-three percent of patients, voiding disorders, bone pain, elevated PSA average, and high Gleason score support the delay in consultation and thus explain the locally advanced or metastatic prostate cancer in our exercise setting. This finding is also reported by many African writers [<xref ref-type="bibr" rid="scirp.84487-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.84487-ref6">6</xref>] . The high level of PSA corroborates well the development of the metastasis objectified by the extented assessment. The predominance of individualized bone metastasis in bone scintigraphy reinforces the thesis of the osteophilic character of prostate cancer and thus explains bone pain symptomatology reported by patients.</p><p>Radical laparoscopic prostatectomy is performed only in a small proportion because of the locally advanced or metastatic prostate cancer requiring thus to practice hormone therapy sometimes associated with chemotherapy in case of resistance to castration. Surgical hormone therapy, synonymous with castration, is very poorly experienced in our context for fear of loss of sexuality and explains the mistrust of some patients to benefit adequate management. Indeed the bilateral orchidectomy, due to the physical absence of the testicles is responsible for a psychological impact dreaded by the patients.</p></sec><sec id="s5"><title>5. Conclusion</title><p>Prostate cancer is common in Douala where patients usually consult at a late stage or metastatic stage. Radical treatment by laparoscopic prostatectomy is available for localized cancers. Improving management requires screening and early consultation.</p></sec><sec id="s6"><title>Cite this paper</title><p>Kamadjou, C., Rimtebaye, K., Eyongeta, D., Kameni, A., Kamga, J. and Njinou, B. (2018) Diagnosis and Management of Prostate Cancer in Urology. Open Journal of Urology, 8, 161-165. https://doi.org/10.4236/oju.2018.85016</p></sec></body><back><ref-list><title>References</title><ref id="scirp.84487-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Villers, A. (2008) Epidémiologie du cancer de la prostate : Article de revue Elsevier. 32, 2-4.</mixed-citation></ref><ref id="scirp.84487-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Siegel, R.L., Miller, K.D. and Jemal, A. (2015) Cancer Statistics, 2015. CA: A Cancer Journal for Clinicians, 65, 5-29. https://doi.org/10.3322/caac.21254</mixed-citation></ref><ref id="scirp.84487-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Oluwole, O.P., Rafindadi, A.H., Shehu, M.S. and Samaila, M.O.A. (2015) A Ten-Year Study of prostate Cancer Specimens at Ahmadu Bello University Teaching Hospital Zaria. Nigeria African Journal of Urology, 21, 15-18.  
https://doi.org/10.1016/j.afju.2014.09.004</mixed-citation></ref><ref id="scirp.84487-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">American Cancer Society (2008) Cancer Facts &amp; Figures 2008. American Cancer Society, Atlanta.</mixed-citation></ref><ref id="scirp.84487-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Amin, M., Boccon-Gibod, L., Egevad, L., Epstein, J.I., Humphrey, P.A., Mikuz, G., et al. (2005) Prognostic and Predictive Factors and Reporting of Prostate Carcinoma in Prostate Needle Biopsy Specimens. Scandinavian Journal of Urology and Nephrology, 216, 20-33. https://doi.org/10.1080/03008880510030923</mixed-citation></ref><ref id="scirp.84487-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ndoye, M., Niang, L., Gandaho, K.I., Jalloh, M., Labou, I. and Gueye, S. (2014) Cancer avancé de la prostate au Sénégal. Aspects diagnostiques à l’h&amp;ocirc;pital de Grand Yoff. Progrès en Urologie, 24, 271-275. https://doi.org/10.1016/j.purol.2013.08.317</mixed-citation></ref><ref id="scirp.84487-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Osegbe, D.N. (1997) Prostate Cancer in Nigerians: Facts and Nonfacts. Journal of Urology, 157, 1340-1343. https://doi.org/10.1016/S0022-5347(01)64966-8</mixed-citation></ref><ref id="scirp.84487-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Odedina, F.T., Akinremi, T.O., Chinegwundoh, F., Roberts, R., Yu, D., Reams, R.R. and Kumar, N. (2009) Prostate Cancer Disparities in Black Men of African Descent: A Comparative Literature Review of Prostate Cancer Burden among Black Men in the United States, Caribbean, United Kingdom, and West Africa. Infectious Agents and Cancer, 4, S2. https://doi.org/10.1186/1750-9378-4-S1-S2</mixed-citation></ref><ref id="scirp.84487-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gueye, S.M., Zeigler-Johnson, C.M., Friebel, T., Spangler, E., Jalloh, M., MacBride, S., et al. (2003) Clinical Characteristics of Prostate Cancer in African Americans, American Whites, and Senegalese Men. Urology, 61, 987-992. 
https://doi.org/10.1016/S0090-4295(02)02588-8</mixed-citation></ref><ref id="scirp.84487-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Milton, S.B., Venceslau, R.S., Gladston, B.S., Alexandre, H. and Marco, A.S. (2003) Prevalence of Prostate Adenocarcinoma According to Race in a University Hospital. International Brazilian Journal of Urology, 29, 306-312. 
https://doi.org/10.1590/S1677-55382003000400004</mixed-citation></ref><ref id="scirp.84487-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Akang, E.E., Aligbe, J.U. and Olisa, E.G. (1996) Prostatic Tumours in Benin City, Nigeria. West African Journal of Medicine, 15, 56-60.</mixed-citation></ref><ref id="scirp.84487-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Echimane, A.K., Ahnoux, A.A., Adoubi, I., Hien, S., M’Bra, K., D’Horpock, A., et al. (2000) Cancer Incidence in Abidjan, Ivory Coast: First Results from Cancer Registry. Cancer, 89, 653-663.  
https://doi.org/10.1002/1097-0142(20000801)89:3&lt;653::AID-CNCR22&gt;3.0.CO;2-Z</mixed-citation></ref><ref id="scirp.84487-ref13"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Angwafo</surname><given-names> F.F. </given-names></name>,<etal>et al</etal>. (<year>1998</year>)<article-title>Migration and Prostate Cancer: An International Perspective</article-title><source> Journal of the National Medical Association</source><volume> 90</volume>,<fpage> S720</fpage>-<lpage>S723</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.84487-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Carter, H.B., Albertsen, P.C., Barry, M.J., Etzioni, R., Freedland, S.J., Greene, K.L., et al. (2013) Early Detection of Prostate Cancer: AUA Guideline. Journal of Urology, 190, 419-426. https://doi.org/10.1016/j.juro.2013.04.119</mixed-citation></ref></ref-list></back></article>